Meloxicam
- Generic Name
- Meloxicam
- Brand Names
- Anjeso, Mobic, Qmiiz, Vivlodex
- Drug Type
- Small Molecule
- Chemical Formula
- C14H13N3O4S2
- CAS Number
- 71125-38-7
- Unique Ingredient Identifier
- VG2QF83CGL
- Background
Meloxicam is a nonsteroidal anti-inflammatory drug (NSAID) used to relieve various types of pain, including pain caused by musculoskeletal conditions, osteoarthritis, and rheumatoid arthritis. With a longer half-life than most other NSAIDS, it is a favorable option for those who require once-daily dosing. Meloxicam is available in oral, transdermal, and intravenous formulations. It is a preferential COX-2 inhibitor, purportedly reducing the risk of adverse gastrointestinal tract effects, however, this is a topic of controversy.
- Indication
Meloxicam is indicated for the symptomatic treatment of arthritis and osteoarthritis. In addition, it is indicated for the pauciarticular and polyarticular course of Juvenile Rheumatoid Arthritis (JRA) in patients aged 2 years old or above. Off-label uses include the treatment of dental or post-surgical pain. In addition to the above, meloxicam has also been studied in the treatment of neuropathic pain.
Meloxicam, in combination with bupivacaine, is indicated for postsurgical analgesia in adult patients for up to 72 hours following foot and ankle, small-to-medium open abdominal, and lower extremity total joint arthroplasty surgical procedures.
- Associated Conditions
- Dental Pain, Neuropathic Pain, Osteoarthritis (OA), Pain, Inflammatory, Pauciarticular juvenile rheumatoid arthritis, Polyarticular juvenile rheumatoid arthritis, chronic or unspecified, Postoperative pain, Rheumatoid Arthritis
Study of Association of Anti-inflammatory and Anti-rheumatic
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2015-05-19
- Last Posted Date
- 2015-05-19
- Lead Sponsor
- Zodiac Produtos Farmaceuticos S.A.
- Target Recruit Count
- 375
- Registration Number
- NCT02448199
Meloxicam SoluMatrix® Capsules vs Meloxicam Tablets to Treat Osteoarthritis Pain
- Conditions
- Osteoarthritis
- Interventions
- First Posted Date
- 2015-04-01
- Last Posted Date
- 2015-07-10
- Lead Sponsor
- Iroko Pharmaceuticals, LLC
- Registration Number
- NCT02405793
Prospective Analgesic Compound Efficacy (PACE) Study
- Conditions
- RadiculopathyGoutMuscle SpasmsHeadacheArthritisSynovitisMigraineTendonitis
- First Posted Date
- 2015-03-31
- Last Posted Date
- 2018-02-01
- Lead Sponsor
- Express Specialty Pharmacy
- Target Recruit Count
- 300
- Registration Number
- NCT02403687
Clinical Study About the Role of COX-2 Inhibitor in Liver Cirrhosis With Biliary Atresia
- Conditions
- Biliary Atresia, Kasai Portoenterostomy Status
- Interventions
- First Posted Date
- 2014-11-21
- Last Posted Date
- 2014-11-21
- Lead Sponsor
- Yonsei University
- Target Recruit Count
- 50
- Registration Number
- NCT02298218
Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea
- Conditions
- Dysmenorrhea
- Interventions
- First Posted Date
- 2014-10-02
- Last Posted Date
- 2019-05-03
- Lead Sponsor
- Laboratorios Andromaco S.A.
- Target Recruit Count
- 68
- Registration Number
- NCT02255045
- Locations
- 🇨🇱
Instituto Chileno de Medicina Reproductiva (ICMER), Santiago, Chile
Efficacy and Safety of Meloxicam Suspension Versus Diclofenac Suspension or Nimesulide Suspension in Patients With a Diagnosis of Acute, Non-bacterial Pharyngitis, Pharyngotonsillitis or Laryngitis
- First Posted Date
- 2014-09-01
- Last Posted Date
- 2014-09-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 128
- Registration Number
- NCT02229747
Effect of Steady State Meloxicam on Low Dose Aspirin Induced Inhibition of Platelet Aggregation and Thromboxane Synthesis in Healthy Males and Females
- First Posted Date
- 2014-07-11
- Last Posted Date
- 2014-07-14
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT02187562
Observational Study of Meloxicam in Mexican Patients With Rheumatic Diseases
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 22639
- Registration Number
- NCT02184065
Safety and Efficacy of Mobic® Ampoules in the Initiation of Treatment of Painful Exacerbations of Osteoarthritis, Rheumatoid Arthritis and Other Similar Painful Inflammatory Conditions
- First Posted Date
- 2014-07-09
- Last Posted Date
- 2014-07-09
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 121
- Registration Number
- NCT02184052
Study to Compare Prescription Non-Steroidal Anti-Inflammatory Drug (NSAID) Changes, Health Care Utilization, Efficacy and Safety of Meloxicam 7.5 mg Versus Usual Care Administration of Prescription NSAIDs in a Managed Healthcare Setting in Patients With Osteoarthritis
- First Posted Date
- 2014-07-08
- Last Posted Date
- 2014-07-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 1309
- Registration Number
- NCT02183064
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.